Related Experiment Video
Updated: Feb 18, 2026

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
Caval Valve Implantation
Alexander Lauten1, Henryk Dreger1, Michael Laule1
1Department of Cardiology, Charité - Universitaetsmedizin Berlin, German Centre for Cardiovascular Research (DZHK), University Heart Center, Charitéplatz 1, Berlin D-10117, Germany.
Insights
Transcatheter therapies offer new options for heart valve disease. This review explores caval valve implantation for severe tricuspid regurgitation, considering patient heterogeneity and treatment success factors.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Transcatheter therapies are expanding treatment options for heart valve disease.
- Tricuspid regurgitation (TR) is a complex condition with a heterogeneous patient population.
- Understanding the natural history of TR is crucial for effective treatment.
Purpose of the Study:
- To review the pathophysiologic background of severe tricuspid regurgitation.
- To examine the current evidence for caval valve implantation (CVI).
- To assess the potential role of CVI in treating severe TR.
Main Methods:
- Literature review of pathophysiologic mechanisms of TR.
- Analysis of current clinical evidence for caval valve implantation.
- Evaluation of patient selection criteria for interventional TR treatment.
Main Results:
- Severe tricuspid regurgitation presents a heterogeneous patient cohort.
- The optimal interventional approach for functional and clinical success remains unclear.
- Caval valve implantation is an emerging option for specific TR subtypes.
Conclusions:
- Further research is needed to determine the best interventional strategies for TR.
- Caval valve implantation shows potential for treating severe tricuspid regurgitation.
- Personalized treatment approaches are essential for this heterogeneous patient group.
Abstract:
Recently, transcatheter therapy has expanded the treatment options for patients with heart valve disease. With the growing understanding of tricuspid regurgitation and its natural history, it becomes increasingly obvious that this patient population is a heterogeneous cohort presenting for treatment in different stages of a continuous disease process. It is still unclear which interventional approach will result in functional and clinical success and in which subtype of patient population. This article reviews the pathophysiologic background and current evidence for caval valve implantation and examines the potential role of this approach for the treatment of severe tricuspid regurgitation.
Related Concept Videos
Mitral Valve Prolapse I: Introduction
Mitral Valve Prolapse II: Assessment and Management
Mitral Valve Prolapse III: Nursing Management
Heart Valves
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
Mitral Stenosis I: Introduction
Mitral Regurgitation I: Introduction

